Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S.

John M. Wentworth, Kim M. Dalziel, Paul E. O'Brien, Paul Burton, Frackson Shaba, Philip M. Clarke, Neda Laiteerapong, Wendy A. Brown

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Aim To determine the cost-effectiveness of gastric band surgery in overweight but not obese people who receive standard diabetes care. Method A microsimulation model (United Kingdom Prospective Diabetes Study outcomes model) was used to project diabetes outcomes and costs from a two-year Australian randomized trial of gastric band (GB) surgery in overweight but not obese people (BMI 25 to 30kg/m2) on to a comparable population of U.S. adults from the National Health and Nutrition Examination Survey (N = 254). Estimates of cost-effectiveness were calculated based on the incremental cost-effectiveness ratios (ICERs) for different treatment scenarios. Costs were inflated to 2015 U.S. dollar values and an ICER of less than $50,000 per QALY gained was considered cost-effective. Results The incremental cost-effectiveness ratio for GB surgery at two years exceeded $90,000 per quality-adjusted life year gained but decreased to $52,000, $29,000 and $22,000 when the health benefits of surgery were assumed to endure for 5, 10 and 15 years respectively. The cost-effectiveness of GB surgery was sensitive to utility gained from weight loss and, to a lesser degree, the costs of GB surgery. However, the cost-effectiveness of GB surgery was affected minimally by improvements in HbA1c, systolic blood pressure and cholesterol. Conclusions GB surgery for overweight but not obese people with T2D appears to be cost-effective in the U.S. setting if weight loss endures for more than five years. Health utility gained from weight loss is a critical input to cost-effectiveness estimates and therefore should be routinely measured in populations undergoing bariatric surgery.

Original languageEnglish
Pages (from-to)1139-1144
Number of pages6
JournalJournal of Diabetes and its Complications
Volume31
Issue number7
DOIs
Publication statusPublished - 1 Jul 2017

Keywords

  • Bariatric surgery
  • Cost-effectiveness
  • Gastric band surgery
  • Overweight but not obese
  • Type 2 diabetes

Cite this

@article{c325b9631f5b4f9298d0eccf647fd9a7,
title = "Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S.",
abstract = "Aim To determine the cost-effectiveness of gastric band surgery in overweight but not obese people who receive standard diabetes care. Method A microsimulation model (United Kingdom Prospective Diabetes Study outcomes model) was used to project diabetes outcomes and costs from a two-year Australian randomized trial of gastric band (GB) surgery in overweight but not obese people (BMI 25 to 30kg/m2) on to a comparable population of U.S. adults from the National Health and Nutrition Examination Survey (N = 254). Estimates of cost-effectiveness were calculated based on the incremental cost-effectiveness ratios (ICERs) for different treatment scenarios. Costs were inflated to 2015 U.S. dollar values and an ICER of less than $50,000 per QALY gained was considered cost-effective. Results The incremental cost-effectiveness ratio for GB surgery at two years exceeded $90,000 per quality-adjusted life year gained but decreased to $52,000, $29,000 and $22,000 when the health benefits of surgery were assumed to endure for 5, 10 and 15 years respectively. The cost-effectiveness of GB surgery was sensitive to utility gained from weight loss and, to a lesser degree, the costs of GB surgery. However, the cost-effectiveness of GB surgery was affected minimally by improvements in HbA1c, systolic blood pressure and cholesterol. Conclusions GB surgery for overweight but not obese people with T2D appears to be cost-effective in the U.S. setting if weight loss endures for more than five years. Health utility gained from weight loss is a critical input to cost-effectiveness estimates and therefore should be routinely measured in populations undergoing bariatric surgery.",
keywords = "Bariatric surgery, Cost-effectiveness, Gastric band surgery, Overweight but not obese, Type 2 diabetes",
author = "Wentworth, {John M.} and Dalziel, {Kim M.} and O'Brien, {Paul E.} and Paul Burton and Frackson Shaba and Clarke, {Philip M.} and Neda Laiteerapong and Brown, {Wendy A.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.jdiacomp.2017.04.009",
language = "English",
volume = "31",
pages = "1139--1144",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier",
number = "7",

}

Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S. / Wentworth, John M.; Dalziel, Kim M.; O'Brien, Paul E.; Burton, Paul; Shaba, Frackson; Clarke, Philip M.; Laiteerapong, Neda; Brown, Wendy A.

In: Journal of Diabetes and its Complications, Vol. 31, No. 7, 01.07.2017, p. 1139-1144.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S.

AU - Wentworth, John M.

AU - Dalziel, Kim M.

AU - O'Brien, Paul E.

AU - Burton, Paul

AU - Shaba, Frackson

AU - Clarke, Philip M.

AU - Laiteerapong, Neda

AU - Brown, Wendy A.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Aim To determine the cost-effectiveness of gastric band surgery in overweight but not obese people who receive standard diabetes care. Method A microsimulation model (United Kingdom Prospective Diabetes Study outcomes model) was used to project diabetes outcomes and costs from a two-year Australian randomized trial of gastric band (GB) surgery in overweight but not obese people (BMI 25 to 30kg/m2) on to a comparable population of U.S. adults from the National Health and Nutrition Examination Survey (N = 254). Estimates of cost-effectiveness were calculated based on the incremental cost-effectiveness ratios (ICERs) for different treatment scenarios. Costs were inflated to 2015 U.S. dollar values and an ICER of less than $50,000 per QALY gained was considered cost-effective. Results The incremental cost-effectiveness ratio for GB surgery at two years exceeded $90,000 per quality-adjusted life year gained but decreased to $52,000, $29,000 and $22,000 when the health benefits of surgery were assumed to endure for 5, 10 and 15 years respectively. The cost-effectiveness of GB surgery was sensitive to utility gained from weight loss and, to a lesser degree, the costs of GB surgery. However, the cost-effectiveness of GB surgery was affected minimally by improvements in HbA1c, systolic blood pressure and cholesterol. Conclusions GB surgery for overweight but not obese people with T2D appears to be cost-effective in the U.S. setting if weight loss endures for more than five years. Health utility gained from weight loss is a critical input to cost-effectiveness estimates and therefore should be routinely measured in populations undergoing bariatric surgery.

AB - Aim To determine the cost-effectiveness of gastric band surgery in overweight but not obese people who receive standard diabetes care. Method A microsimulation model (United Kingdom Prospective Diabetes Study outcomes model) was used to project diabetes outcomes and costs from a two-year Australian randomized trial of gastric band (GB) surgery in overweight but not obese people (BMI 25 to 30kg/m2) on to a comparable population of U.S. adults from the National Health and Nutrition Examination Survey (N = 254). Estimates of cost-effectiveness were calculated based on the incremental cost-effectiveness ratios (ICERs) for different treatment scenarios. Costs were inflated to 2015 U.S. dollar values and an ICER of less than $50,000 per QALY gained was considered cost-effective. Results The incremental cost-effectiveness ratio for GB surgery at two years exceeded $90,000 per quality-adjusted life year gained but decreased to $52,000, $29,000 and $22,000 when the health benefits of surgery were assumed to endure for 5, 10 and 15 years respectively. The cost-effectiveness of GB surgery was sensitive to utility gained from weight loss and, to a lesser degree, the costs of GB surgery. However, the cost-effectiveness of GB surgery was affected minimally by improvements in HbA1c, systolic blood pressure and cholesterol. Conclusions GB surgery for overweight but not obese people with T2D appears to be cost-effective in the U.S. setting if weight loss endures for more than five years. Health utility gained from weight loss is a critical input to cost-effectiveness estimates and therefore should be routinely measured in populations undergoing bariatric surgery.

KW - Bariatric surgery

KW - Cost-effectiveness

KW - Gastric band surgery

KW - Overweight but not obese

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85018814039&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2017.04.009

DO - 10.1016/j.jdiacomp.2017.04.009

M3 - Article

VL - 31

SP - 1139

EP - 1144

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 7

ER -